Abstracts tagged "Biologic agents and Churg-Strauss syndrome"

Abstract Number: 1779 • 2017 ACR/ARHP Annual Meeting
Off-Label Use of Biological Therapies in Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)
Laure Denis¹, Maxime Samson², Francois Maurier³, Chahéra Khouatra⁴, Vincent Germain⁵, Xavier Delbrel⁶, Philippe Bonniaud⁷, Alban Deroux⁸, Nicolas Girszyn⁹, Claire de Moreuil¹⁰, Dominique Chauveau¹¹, Anne Gondouin¹², Stephane Dominique¹³, Guillaume Le Guenno¹⁴, Laurence Bouillet¹⁵, Bernard Bonnotte², Jean-Emmanuel Kahn¹⁶, Boris Bienvenu¹⁷, Bertrand Godeau¹⁸, Claire Le Jeunne¹⁹, Xavier Puéchal²⁰, Loïc Guillevin for the French Vasculitis Study Group²⁰ and Benjamin Terrier¹⁹, ¹Internal Medicine, CHU Estaing, Clermont-Ferrand, Clermont-Ferrand, France, ²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ⁴Lyon, Lyon, France, ⁵Rheumatology, CHU Pellegrin, Bordeaux, France, BORDEAUX, France, ⁶Internal Medicine, CH de Pau, PAU, France, ⁷Pulmonology, CHU de Dijon, Dijon, France, ⁸Internal Medicine, CHU de Grenoble, Grenoble, France, ⁹CHU de Rouen, Rouen, France, ¹⁰CHU de Brest, Brest, France, ¹¹Nephrology, CHU de Toulouse, Toulouse, France, ¹²CH de Lons le Saunier, Lons le Saunier, France, ¹³Pulmonology, CHU de Rouen, Rouen, France, ¹⁴Internal Medicine department, Clermont-Ferrand, France, ¹⁵CHU, Grenoble, France, ¹⁶foch hospital, foch, France, ¹⁷Internal Medicine, Hôpital Saint Joseph, Marseille, France, ¹⁸Internal medicine, Hôpital Henri-Mondor, Créteil, France, ¹⁹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ²⁰Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is characterized by pulmonary and systemic small-vessel necrotizing vasculitis, vascular and/or extravascular granulomas, eosinophilia and tissue infiltration by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].